TL;DR
Mesenchymal progenitors (MPs), crucial for tissue repair and immune regulation, were found to maintain a balanced inflammatory state through the TAK1-NFkB pathway. Disrupting this pathway in MPs leads to a pro-Type 2 inflammatory environment, exacerbating Th2-driven diseases like asthma while protecting against Th1/Th17-driven diseases like experimental autoimmune encephalitis.
What Problem Does This Paper Address?
Mesenchymal stromal cells (MSCs), including mesenchymal progenitors (MPs), are a promising therapeutic tool due to their immunomodulatory capabilities. However, their clinical success is hampered by a lack of understanding of their precise role in maintaining immune homeostasis under normal physiological conditions. This paper investigates how MPs, specifically through the TAK1-NFkB signaling pathway, contribute to the baseline inflammatory environment and how manipulating this pathway impacts immune responses and disease outcomes.
Methods
The study utilized a genetically engineered mouse model (HIC1△TAK1) where TAK1 was specifically deleted in Hic1-expressing mesenchymal progenitors. Key techniques included:
- Mass Cytometry (CyTOF): To analyze a broad range of immune cell populations in various tissues and blood.
- Flow Cytometry: To validate CyTOF findings and quantify specific immune cell populations.
- Mesoscale and ELISA: To measure cytokine and IgE levels in serum.
- RNA sequencing (RNAseq): To analyze the gene expression profile of skeletal muscle-resident MPs.
- Gene Ontology (GO) analysis: To identify biological processes affected by TAK1 deletion in MPs.
- Mouse models of disease: Experimental autoimmune encephalomyelitis (EAE) for Th1/Th17-driven disease and papain-induced allergic asthma for Th2-driven disease.
- Genetic manipulation: Crossing HIC1△TAK1 mice with ST2-/- mice (lacking the IL-33 receptor) to investigate the role of ILC2s.
- NF-kB pathway manipulation: Generating a mouse model with dampened NF-kB signaling in HIC1+ cells (HIC1△NEMO).
Datasets
Not discussed in the paper.
Key Insights and Ideas
- MPs as "Inflammatory Milieu Architects": The study reveals that MPs aren't just passive responders but actively shape the baseline inflammatory environment, maintaining a balance between Type 1 and Type 2 immunity.
- TAK1-NFkB Axis is Crucial for Homeostasis: The constitutive activity of the TAK1-NFkB pathway in MPs is essential for preventing a systemic skew towards Type 2 inflammation.
- ILC2s as Key Effectors: The study strongly implicates Type 2 innate lymphoid cells (ILC2s) as the primary mediators of the pro-Type 2 inflammatory phenotype observed when TAK1 is deleted in MPs.
- Therapeutic Implications: Understanding this pathway opens avenues for "locking" MPs into a specific inflammatory state for targeted therapeutic interventions.
Key Results
- Systemic Type 2 Inflammation: HIC1△TAK1 mice exhibited a significant increase in eosinophils and ILC2s, along with elevated Type 2 cytokines (IL-4, IL-5, IL-13) and IgE.
- Impact on Disease Models:
- HIC1△TAK1 mice were protected against Th1/Th17-driven EAE, showing delayed disease onset and milder symptoms.
- HIC1△TAK1 mice showed increased sensitivity to papain-induced allergic asthma, with worsened lung function and inflammation.
- Bone Marrow Hematopoiesis: Deletion of TAK1 in MPs shifted bone marrow hematopoiesis towards granulopoiesis, leading to increased eosinophil progenitors.
- NF-kB Pathway Involvement: Dampening NF-kB signaling in HIC1+ cells phenocopied the HIC1△TAK1 phenotype, confirming the role of the TAK1-NFkB axis.
- ILC2 Dependence: Blocking ILC2 activation (using ST2-/- mice) prevented the hyper-eosinophilia and Type 2 inflammatory environment in HIC1△TAK1 mice.
Limitations and Future Work
- Complexity of MSCs: The paper acknowledges the diverse identities and functions of multipotent stromal cells, suggesting further research is needed to fully delineate their roles.
- Therapeutic Translation: While the study highlights a potential strategy to "lock" MPs into a specific functional state, translating this into safe and effective cell therapies requires further investigation.
- Broader Impact of TAK1: The study focuses on the TAK1-NFkB axis in MPs. Future work could explore other downstream targets of TAK1 in MPs and their contributions to immune regulation.
- Specific Disease Contexts: While the study demonstrates impact in EAE and asthma models, further research is needed to understand how this pathway influences other inflammatory and autoimmune diseases.
Summary updated